Neumora Therapeutics Q2 2025 Earnings Report

Neumora Therapeutics EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.38
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Neumora Therapeutics Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Neumora Therapeutics Announcement Details

• Quarter: Q2 2025
• Date: 8/5/2025
• Time: Before Market Opens
• Conference Call Date: Monday, August 11, 2025
• Conference Call Time: 12:30PM ET

Neumora Therapeutics (NASDAQ:NMRA) (NASDAQ: NMRA) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of treatments for central nervous system (CNS) disorders. The company’s research platform integrates computational biology, medicinal chemistry and high-throughput screening to accelerate the identification of novel small molecules and biologic candidates. Neumora’s focus spans mood disorders, neuropathic pain, epilepsy and movement disorders, addressing significant unmet medical needs in psychiatric and neurological care.

At the core of Neumora’s pipeline are several lead programs: an investigational therapy targeting synaptic modulation for treatment-resistant depression and suicidality; a small molecule designed to modulate excitatory pathways in refractory epilepsy; and additional assets aimed at neuropathic pain and Parkinson’s disease. Each program is supported by biomarker-driven clinical trials and preclinical studies, leveraging translational science to optimize patient selection and demonstrate proof of concept.

Founded in 2019 as Day One Biopharma and rebranded to Neumora Therapeutics in 2021, the company is headquartered in Boston, Massachusetts, with research collaborations across North America and Europe. Neumora has established partnerships with leading academic centers and contract research organizations to advance its CNS portfolio. The company’s global footprint aims to facilitate multi-regional clinical trials and streamline regulatory interactions in key markets.

Neumora’s leadership team combines deep expertise in neuroscience drug development and operations. Douglas Cole serves as President and Chief Executive Officer, bringing over two decades of experience in biopharma strategy and R&D. The executive team includes seasoned professionals in clinical development, regulatory affairs and chemistry, manufacturing and controls (CMC). Under this leadership, Neumora is positioned to translate scientific innovation into new therapies for patients with debilitating neurological and psychiatric conditions.